Take part in the R&D opportunity for developing syndromic molecular UTI and drug resistance panels with the support form the MDx Impact Grants.
Seegene and Accuramed are pleased to announce the Nature Awards MDx Impact Grants to accelerate innovation in UTI and Drug Resistance diagnostics.
Springer Nature and Seegene (with the local Benelux support of Accuramed) are pleased to announce the Nature Awards MDx Impact Grants 2025-2026 with the focus on UTI and Drug Resistance diagnosis
Springer Nature and Seegene invite research groups to develop tests that address unmet clinical needs. The programme provides researchers with access to Seegene’s syndromic PCR technology and development grants of up to 600,000 USD to perform clinical studies.
2025 Scope: Urinary Tract Infection (UTI) Drug Resistance (DR)
This year, the MDx Impact Grants focus on Urinary Tract Infection (UTI) Drug Resistance (DR) genes that correspond to clinically important antibiotic resistance genes, such as, CTX-M, KPC, NDM and vanA. Your proposal must include a minimum of nine (9) and up to a maximum of eighteen (18) target genes excluding internal controls.
All details for applications and the condition can be found through the below link
Smaakt naar meer?
We stellen onze expertise in analyse en advies graag ter beschikking om de beste oplossing voor u, uw organisatie en patiënt samen te stellen. Neem contact en ervaar het verschil.